Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28906185 | 0.80 | LMNA (0.30) | — | |
| SCHEMBL4292592 | 0.78 | GRM2 (0.41) | CYP19A1HPGDALDH1A1TSHRKMT2A | |
| SCHEMBL4142631 | 0.76 | CYP1A2 (0.73) | SMN1; SMN2CYP1A2CYP19A1HPGDMEN1 | |
| SCHEMBL4291497 | 0.76 | GRM2 (0.39) | CYP19A1HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL3669940 | 0.76 | CYP19A1 (0.48) | CYP19A1ALDH1A1TSHRPOLB | |
| SCHEMBL3667322 | 0.73 | ROCK2 (0.43) | CYP19A1HPGDALDH1A1 | |
| SCHEMBL4142636 | 0.73 | SMN1; SMN2 (0.71) | SMN1; SMN2CYP1A2CYP19A1HPGDALDH1A1 | |
| SCHEMBL15510526 | 0.73 | TSHR (0.45) | SMN1; SMN2CYP1A2CYP19A1HPGDALDH1A1 | |
| SCHEMBL27849054 | 0.72 | CYP1A2 (0.56) | SMN1; SMN2CYP1A2CYP19A1HPGDMAPK10 | |
| SCHEMBL4292554 | 0.72 | CDC7 (0.44) | SMN1; SMN2CYP19A1HPGDMAPK8POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | SMN1; SMN2 3653/4885CYP1A2 1030/4885CYP19A1 2191/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | SMN1; SMN2 3653/4885CYP1A2 1030/4885CYP19A1 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.